Supernus Pharmaceuticals Inc (SUPN) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $41.98 (-2.19%), Market cap $2.87B, 52-week low–high $31.16 ~ $57.00.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, a
Financial statements, price targets, institutional (13F) holdings and related news for Supernus Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Supernus Pharmaceuticals Inc trades at $41.98 (-2.19%). Real-time quotes and charts are available on BlackAll Trade.
Supernus Pharmaceuticals Inc has a market cap of about $2.87B.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United State